GN Group to Fully Acquire Ayumi Pharmaceutical Holdings

Tokyo, June 8, 2026 — GN Group Co., Ltd. (TSE: 2160, “the Company”) announced that it has entered into an agreement to acquire all shares of Ayumi Pharmaceutical Holdings Co., Ltd. (“Ayumi Pharmaceutical Holdings”) from shareholders led by Blackstone. The transaction values Ayumi Pharmaceutical Holdings at approximately 44.8 billion yen, and upon completion, the company will become a wholly owned subsidiary of GN Group.

This acquisition will significantly expand GN Group's sales base in Japan, establishing a large-scale pharmaceutical platform expected to accelerate the introduction of innovative drugs, biosimilars, and in-house developed products to the Japanese market.

Ying Luo, CEO of GN Group, commented:

"The acquisition of Ayumi Pharmaceutical by GN Group is a critical milestone in our long-term strategy to establish a leading position in biopharmaceuticals across the Pacific Rim. By integrating Ayumi's strong domestic sales infrastructure and market-leading product portfolio in pain management into our network, we can directly deliver more innovative product pipelines to patients with unmet medical needs in Japan. This transaction is transformative, strengthening our business foundation and accelerating future sales growth. We are also honored to welcome Blackstone, Toho Holdings, and Hisamitsu Pharmaceutical as new shareholders. We will work closely with all stakeholders to drive the next stage of growth for our group."

Atsuhiko Sakamoto, Head of Blackstone's Private Equity in Japan, stated:

"Ayumi Pharmaceutical represents Blackstone's first private equity investment in Japan, embodying our commitment to building strong business foundations. We worked closely with Ayumi's management to strengthen its business, accelerate growth, and establish a market-leading presence. We are proud of Ayumi's current form and look forward to supporting its further growth together with GN Group."

Ayumi Pharmaceutical is a specialty pharmaceutical company with a strong presence in pain management and rheumatology. Its flagship product, Calonal® (acetaminophen), holds over 80% market share in Japan's acetaminophen market. The company also has a broad product portfolio serving patients in rheumatology and orthopedics, with a sales network covering medical institutions nationwide.

For the fiscal year ended March 2026, Ayumi Pharmaceutical reported consolidated revenue of approximately 38.5 billion yen and operating profit of approximately 6.2 billion yen.

Strategic Significance of the Acquisition

- Establishes a large-scale and continuous revenue base in Japan, creating new licensing and commercialization opportunities. - Expands GN Group's capabilities in rheumatology, orthopedics, and pain management through Ayumi's existing products, sales infrastructure, and customer base. - Strengthens the ability to introduce overseas drugs and biosimilars to Japan by leveraging Ayumi's market access and distribution functions. - Diversifies regional revenue streams across Japan, China, and the United States, supporting long-term sustainable growth. - Enhances cash generation and financial stability, and expands future cross-selling and product portfolio synergy opportunities.

The transaction is expected to significantly expand GN Group's scale, including its employee base, product portfolio, and development pipeline. The combined organization will focus on five key therapeutic areas: fibrosis, pain management, rheumatology, oncology, and orthopedics.

About GN Group

GN Group is a global biopharmaceutical company headquartered in Japan with operations in Japan, China, the United States, and Australia. The group is engaged in drug development and sales, drug discovery, and medtech businesses. Its portfolio includes marketed products and a broad pipeline targeting fibrosis, cancer, inflammatory diseases, pain, and other serious conditions.

GN Group's consolidated subsidiary, Gyre Therapeutics, Inc., listed on the NASDAQ in the U.S., is a vertically integrated biopharmaceutical company focused on fibrosis, inflammatory diseases, and oncology. It has a diverse portfolio of marketed products and a robust global pipeline of innovative therapeutics spanning drug discovery, clinical development, and commercialization.

About Ayumi Pharmaceutical Holdings

Ayumi Pharmaceutical Holdings is a Japan-based pharmaceutical company focused on rheumatology, orthopedics, pain management, and contract manufacturing services. It sells a wide range of specialty pharmaceuticals and has manufacturing and sales capabilities for healthcare providers nationwide.

About Blackstone

Blackstone is one of the world's largest alternative asset managers, aiming to deliver attractive returns to institutional and individual investors through value enhancement of portfolio companies. With over $1.3 trillion in assets under management, Blackstone pursues global investment strategies including real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries, and hedge funds. For more information, visit www.blackstone.com.

Contact: GN Group Co., Ltd., Public Relations E-mail: IR@gnipharma.com Tel: 03-6214-3600